公开(公告)号：US20230119423A1

公开(公告)日：2023-04-20

申请号：US17517796

申请日：2021-11-03

申请人： Fu Jen Catholic University

发明人： Fu-Tien Chiang ,  Wei-Chao Chiu

IPC分类号： A61K31/47 ,  A61K31/4152 ,  A61P9/12

摘要： The present disclosure provides a method for treating hypertension by using a compound, wherein the compound is selected from the group consisting of: (E)-4-(3-(3-methyl benzyloxy)benzylidene)-1-phenylpyrazolidine-3,5-dione, (2R)-2-amino-3-(2,3-dihydro-1H-inden-1-yl)-N′-((E)-quinolin-7-ylmethylene)propane hydrazide, and a combination thereof. The present disclosure uses a small molecule compound (E)-4-(3-(3-methyl benzyloxy)benzylidene)-1-phenylpyrazolidine-3,5-dione, (2R)-2-amino-3-(2,3-dihydro-1H-inden-1-yl)-N′-((E)-quinolin-7-ylmethylene)propane hydrazide or a combination thereof, which can be developed as a therapeutic drug for lowering blood pressure, whether it is taken orally or injected.

公开(公告)号：US20230084752A1

公开(公告)日：2023-03-16

申请号：US17609392

申请日：2020-05-14

申请人： Metabomed Ltd.

发明人： Philippe NAKACHE ,  Omri Erez ,  Simone BOTTI ,  Andreas GOUTOPOULOS ,  Harry Finch

IPC分类号： C07D231/22 ,  A61P35/00 ,  A61K31/4152 ,  A61K31/4155 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/497 ,  A61K31/506 ,  A61K45/06 ,  C07D231/20 ,  C07D401/04 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/04 ,  C07D413/12 ,  C07D417/12 ,  A61P31/12 ,  A61P37/02 ,  C07D401/10 ,  C07D413/14 ,  C07D409/12 ,  C07D413/10 ,  C07D405/14 ,  C07F5/02 ,  A61P3/00 ,  A61P29/00 ,  C07D405/04 ,  C07D403/10 ,  C07D231/26 ,  C07D401/14 ,  C07D405/10 ,  C07D403/04 ,  A61P25/00

摘要： The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity/weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory/autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and dmg resistant cancer of various types.

公开(公告)号：US11554110B2

公开(公告)日：2023-01-17

申请号：US17708740

申请日：2022-03-30

申请人： Kowa Company, Ltd.

发明人： Ryu Oshima ,  Masatoshi Ito ,  Chisato Nagai

IPC分类号： A61K31/423 ,  A61K31/34 ,  A61K31/4152 ,  A61K31/427 ,  A61K31/4353 ,  A61K31/4402 ,  A61K31/4433 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/513 ,  A61K31/7034 ,  A61K38/13 ,  A61P3/06 ,  A61K31/7048 ,  A61K45/06

摘要： To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereinafter also referred to as pemafibrate therapy).
A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pemafibrate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.

公开(公告)号：US11452724B2

公开(公告)日：2022-09-27

申请号：US16855623

申请日：2020-04-22

申请人： The Regents of the University of Michigan

发明人： Eva L. Feldman ,  Ben Murdock ,  Stephen Goutman ,  Stacey Jacoby

IPC分类号： C07D487/04 ,  A61K31/519 ,  A61P25/00 ,  A61K9/00 ,  A61K31/428 ,  A61K31/53 ,  A61K31/7105 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/51 ,  A61K31/4152 ,  A61K31/133

摘要： Provided herein are methods for treating, delaying progression of, or reducing the severity of amyotrophic lateral sclerosis (ALS) in a subject through administration of therapeutically effective amounts of agents (e.g., JAK kinase inhibitors (e.g., tofacitinib)) capable of interfering with central nervous system related natural killer cell (NK) levels and function.

公开(公告)号：US11439649B2

公开(公告)日：2022-09-13

申请号：US16987542

申请日：2020-08-07

申请人： AI Therapeutics, Inc.

发明人： Henri Lichenstein ,  Sean Landrette ,  Peter R. Young ,  Jonathan M. Rothberg

IPC分类号： A61K31/5375 ,  A61K31/675 ,  A61K31/66 ,  A61K31/498 ,  A61K31/4152 ,  A61K31/5377 ,  A61P25/00 ,  A61K9/00 ,  A61K31/428 ,  A61P25/28 ,  A61K45/06 ,  A61P25/08

摘要： Provided are compositions and methods related to the use of apilimod in combination with glutamatergic agents for treating neurological diseases and disorders, and for the treatment of cancer.

公开(公告)号：US20220265615A1

公开(公告)日：2022-08-25

申请号：US17689666

申请日：2022-03-08

申请人： Stealth BioTherapeutics Inc.

发明人： Dennis Keefe ,  Guozhu Zheng ,  Vania Broccoli

IPC分类号： A61K31/4245 ,  A61P25/28 ,  A61K31/135 ,  A61K31/197 ,  A61K31/4152 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/5513 ,  A61K38/30

摘要： The present disclosure provides novel methods for treating or preventing amyotrophic lateral sclerosis (ALS), methods for delaying the onset of neurological symptoms associated with ALS, increasing survival in subjects afflicted with ALS, and attenuating the decline of muscle strength associated with ALS in a subject in need thereof. The present disclosure also provides methods for treating or preventing α-synucleinopathy or TDP-43 proteinopathy. The methods comprise administering to the subject an effective amount of a mitochondria-targeting peptidomimetic compound, such as (R)-2-amino-N-((S)-1-(((S)-5-amino-1-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-yl)-5-guanidinopentanamide, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and/or solvate thereof.

公开(公告)号：US11406625B2

公开(公告)日：2022-08-09

申请号：US16789564

申请日：2020-02-13

申请人： PRILENIA NEUROTHERAPEUTICS LTD.

发明人： Michal Geva ,  Ralph Laufer ,  Michael Hayden ,  Neta Zach

IPC分类号： A61K31/44 ,  A61P25/14 ,  A61K9/00 ,  A61K31/185 ,  A61K31/222 ,  A61K31/4152 ,  A61K31/426 ,  A61K31/4748 ,  A61K31/49

摘要： Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine as monotherapy or together with riluzole, edaravone, combination of dextromethorphan/quinidine, sodium phenylbutyrate (PB), tauroursodeoxycholic acid or combination of sodium phenylbutyrate (PB)/tauroursodeoxycholic acid (i.e. AMX0035) as combination or add-on therapy.

公开(公告)号：US20220151958A1

公开(公告)日：2022-05-19

申请号：US17527987

申请日：2021-11-16

申请人： The Feinstein Institutes for Medical Research

发明人： Lance BECKER ,  Rishabh Charan Choudhary

IPC分类号： A61K31/155 ,  A61K31/198 ,  A61K31/765 ,  A61K31/122 ,  A61K38/13 ,  A61K31/4152 ,  A61K31/165 ,  A61K31/506 ,  A61K31/375 ,  A61K31/4709 ,  A61K47/22 ,  A61P9/10

摘要： The present disclosure relates to compositions, methods of preparation of the compositions, and methods including administration of said compositions for the prevention of neurological damage associated with cerebral ischemia.

公开(公告)号：US20220142982A1

公开(公告)日：2022-05-12

申请号：US17564538

申请日：2021-12-29

申请人： MITSUBISHI TANABE PHARMA CORPORATION

发明人： Hidetoshi SHIMIZU ,  Yoshinobu NAKAMARU ,  Yukiko NISHIMURA

IPC分类号： A61K31/4152 ,  A61P25/28 ,  A61K9/00

摘要： A method of treating an oxidative stress disease includes orally or intragastrically administering, to a subject in need thereof, a pharmaceutical composition including edaravone with a time interval from a consumption of a meal by the subject in need thereof to an administration of the pharmaceutical composition to the subject in need thereof. The time interval is 8 hours or longer after the consumption of a high-fat meal, the time interval is 4 hours or longer after the consumption of a standard meal, or the time interval is 2 hours or longer after the consumption of a light meal.

公开(公告)号：US20220079986A1

公开(公告)日：2022-03-17

申请号：US17424985

申请日：2020-01-23

申请人： The General Hospital Corporation

发明人： Mark C. POZNANSKY ,  Ruxandra F. SIRBULESCU

IPC分类号： A61K35/17 ,  A61K31/4152 ,  A61K31/428 ,  A61K45/06 ,  A61P25/28

摘要： The invention, in general, features a method of treating a neurodegenerative disease (such as amyotrophic lateral sclerosis) or a traumatic brain injury in a subject (e.g., a human) in need thereof, the method comprising administering to the subject a therapeutically effective amount of isolated B cells (such as autologous or allogeneic or xenogeneic B cells).